# OnCo record gallbladder (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/gallbladder/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "gallbladder" ;
  schema:name "Gallbladder cancer"@en ;
  schema:alternateName "Gallbladder cancer"@en, "Gallbladder carcinoma"@en, "Carcinoma of the gallbladder"@en, "Gall bladder cancer"@en, "Biliary tract cancer of the gallbladder"@en, "GBC"@en, "ICD-10 C23"@en ;
  schema:description "Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."@en ;
  schema:url <https://onco.cc/cancers/gallbladder/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Gallbladder_cancer> ;
  schema:citation <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/types>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/stages-and-grades>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/risks-causes>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/survival>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/getting-diagnosed/screening>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/incidence>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/mortality>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/survival>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/risk-factors>, <https://www.nhs.uk/conditions/gallbladder-cancer/>, <https://www.nhs.uk/conditions/gallbladder-cancer/symptoms/>, <https://www.nhs.uk/conditions/gallbladder-cancer/causes/>, <https://www.nhs.uk/conditions/gallbladder-cancer/tests-and-next-steps/>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/12-gallbladder-fact-sheet.pdf>, <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer>, <https://www.cancer.gov/types/gallbladder>, <https://doi.org/10.1038/s41572-022-00398-y>, <https://doi.org/10.2147/clep.s37357>, <https://doi.org/10.1002/ijc.21683>, <https://doi.org/10.1158/1055-9965.epi-15-0199>, <https://doi.org/10.1007/s40615-026-02959-3>, <https://doi.org/10.1097/coc.0000000000000918>, <https://doi.org/10.1016/j.canep.2025.102958>, <https://doi.org/10.1046/j.1440-1746.2003.03066.x>, <https://doi.org/10.1371/journal.pone.0108498>, <https://doi.org/10.1001/jama.1983.03340170049027>, <https://doi.org/10.4178/epih.e2021011>, <https://doi.org/10.1038/ajg.2016.345>, <https://doi.org/10.1007/s11605-013-2170-0>, <https://doi.org/10.1016/j.jamcollsurg.2017.11.026>, <https://doi.org/10.1016/j.ijsu.2016.07.061>, <https://doi.org/10.1007/s00330-021-08384-w>, <https://doi.org/10.1097/01.pas.0000213435.99492.8a>, <https://doi.org/10.1111/liv.14326>, <https://doi.org/10.1002/cam4.915>, <https://doi.org/10.1002/jhbp.12187>, <https://doi.org/10.12659/msmbr.901651>, <https://doi.org/10.1053/j.gastro.2017.04.005>, <https://doi.org/10.1001/jama.2015.4559>, <https://doi.org/10.1016/s1470-2045(17)30167-5>, <https://doi.org/10.1371/journal.pgen.1006756>, <https://doi.org/10.3390/cancers15164033>, <https://doi.org/10.1111/hpb.12444>, <https://doi.org/10.1002/bjs.11035>, <https://doi.org/10.1001/jamasurg.2016.3642>, <https://doi.org/10.1016/j.surg.2016.08.007>, <https://doi.org/10.1093/bjsopen/zrae013>, <https://doi.org/10.61409/a11240787>, <https://doi.org/10.1097/sla.0000000000000728>, <https://doi.org/10.1016/j.hpb.2021.12.019>, <https://doi.org/10.4143/crt.2019.271>, <https://doi.org/10.3390/cancers13030547>, <https://doi.org/10.1186/1477-7819-10-87>, <https://doi.org/10.14701/ahbps.26-091>, <https://doi.org/10.1016/j.hpb.2024.01.012>, <https://doi.org/10.3389/fonc.2023.1186378>, <https://doi.org/10.1097/mnm.0000000000001405>, <https://doi.org/10.1016/j.clinimag.2012.05.009>, <https://doi.org/10.1016/j.ejrad.2018.11.034>, <https://doi.org/10.4240/wjgs.v14.i11.1272>, <https://doi.org/10.1002/jso.26726>, <https://doi.org/10.1097/js9.0000000000001456>, <https://doi.org/10.1007/s00428-013-1478-1>, <https://doi.org/10.1111/his.13975>, <https://doi.org/10.1097/md.0000000000022292>, <https://doi.org/10.1007/s00423-020-02075-8>, <https://doi.org/10.1056/EVIDoa2200015>, <https://doi.org/10.1016/S0140-6736(23)00727-4>, <https://doi.org/10.1016/S1470-2045(23)00242-5>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517>, <https://www.nhs.uk/conditions/gallbladder-cancer/treatment/>, <https://www.nhs.uk/conditions/gallbladder-cancer/help-and-support/>, <https://www.macmillan.org.uk/cancer-information-and-support/gallbladder-cancer>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/treatment-decisions>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/follow-up>, <https://ammf.org.uk/>, <https://ammf.org.uk/second-opinions-and-liver-disease-centres/>, <https://www.esmo.org/for-patients/patient-guides/biliary-tract-cancer-a-guide-for-patients>, <https://www.nice.org.uk/guidance/ta944>, <https://www.cancerresearchuk.org/about-cancer/treatment/prehabilitation>, <https://doi.org/10.1016/S1470-2045(18)30915-X>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/chemotherapy>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/immunotherapy>, <https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/surgery>, <https://www.cbioportal.org/study/summary?id=gbc_mskcc_2022>, <https://www.cbioportal.org/study/summary?id=gbc_msk_2018>, <https://www.cbioportal.org/study/summary?id=gbc_shanghai_2014>, <https://doi.org/10.1158/1078-0432.ccr-22-1954>, <https://doi.org/10.1200/go-25-00332>, <https://doi.org/10.1200/go.24.00090>, <https://www.nice.org.uk/guidance/conditions-and-diseases/cancer/biliary-tract-cancers/products>, <https://gco.iarc.who.int/today>, <https://ncdirindia.org/All_Reports/Report_2020/resources/Chapter5ComparisonofcancerincidenceandpatternsofallPopulationBasedCancerRegistries.pdf>, <https://www.supersalud.gob.cl/difusion/665/w3-propertyvalue-1962.html>, <https://ganjoho.jp/reg_stat/statistics/stat/cancer/9_gallbladder.html>, <https://doi.org/10.1016/j.annonc.2022.10.506>, <https://doi.org/10.1093/bjs/znag050> ;
  onco:tag "gallbladder", "biliary", "nci-coverage", "rare" ;
  onco:related <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/ampullary/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/gallbladder-adenocarcinoma/>, <https://onco.cc/cancers/incidental-gallbladder-cancer/>, <https://onco.cc/collections/globocan/>, <https://onco.cc/collections/seer/>, <https://onco.cc/biomarkers/her2-ihc-3-plus/>, <https://onco.cc/biomarkers/her2-ihc-2-plus/>, <https://onco.cc/biomarkers/her2-ish-amplified/>, <https://onco.cc/biomarkers/her2-mutation/>, <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/tmb-high/>, <https://onco.cc/biomarkers/ntrk-fusion/>, <https://onco.cc/biomarkers/pd-l1-tps/>, <https://onco.cc/biomarkers/pd-l1-cps/>, <https://onco.cc/biomarkers/braf-v600e/>, <https://onco.cc/roadmaps/gallbladder-cancer-roadmap/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/enteral-parenteral-nutrition/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/gallbladder-cancer-surgery/>, <https://onco.cc/technologies/sbrt/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/cdkn2a/>, <https://onco.cc/targets/cdkn2b/>, <https://onco.cc/targets/arid1a/>, <https://onco.cc/targets/smad4/>, <https://onco.cc/targets/ctnnb1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/mdm2/>, <https://onco.cc/targets/idh/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/mmr/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/palb2/>, <https://onco.cc/targets/elf3/>, <https://onco.cc/targets/stk11/>, <https://onco.cc/targets/ccne1/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/ventana-mmr-rxdx/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/zanidatamab-zovodotin/>, <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/varlitinib/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/>, <https://onco.cc/drugs/ivonescimab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/jazz/> ;
  onco:institutions <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/nice/>, <https://onco.cc/institutions/ammf/>, <https://onco.cc/institutions/kings-college-hospital-london/>, <https://onco.cc/institutions/liverpool-hpb-centre/>, <https://onco.cc/institutions/royal-free-hospital/>, <https://onco.cc/institutions/birmingham-cancer-centre/>, <https://onco.cc/institutions/leeds-cancer-centre/>, <https://onco.cc/institutions/newcastle-cancer-centre/>, <https://onco.cc/institutions/southampton-cancer/> ;
  onco:pathways <https://onco.cc/pathways/inflammation-nfkb/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/p53-mdm2-axis/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/mismatch-repair-msi/> ;
  onco:terms <https://onco.cc/terms/porcelain-gallbladder/>, <https://onco.cc/terms/gallbladder-polyp/>, <https://onco.cc/terms/simple-cholecystectomy/>, <https://onco.cc/terms/radical-cholecystectomy/>, <https://onco.cc/terms/segment-ivb-v-resection/>, <https://onco.cc/terms/port-site-metastasis/>, <https://onco.cc/terms/t2a-versus-t2b/>, <https://onco.cc/terms/rokitansky-aschoff-sinus/>, <https://onco.cc/terms/anomalous-pancreaticobiliary-junction/>, <https://onco.cc/terms/cystic-duct-margin/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/biliary-anatomy-subtypes/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/staging-laparoscopy/>, <https://onco.cc/terms/carcinoma-in-situ/>, <https://onco.cc/terms/dysplasia/>, <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/peritoneal-metastasis/>, <https://onco.cc/cancers/incidental-gallbladder-cancer/>, <https://onco.cc/terms/stent-or-bypass-for-jaundice/>, <https://onco.cc/terms/genomic-testing-biliary-uk/>, <https://onco.cc/terms/trial-or-standard-treatment-biliary/>, <https://onco.cc/terms/jaundice-and-itch-biliary/>, <https://onco.cc/terms/biliary-stent-problems/>, <https://onco.cc/terms/acute-cholangitis/>, <https://onco.cc/terms/pain-with-biliary-cancer/>, <https://onco.cc/terms/weight-loss-and-fat-digestion-biliary/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/eating-after-gallbladder-removal/>, <https://onco.cc/terms/urgent-help-gallbladder-cancer/>, <https://onco.cc/terms/emotional-support-cancer-uk/>, <https://onco.cc/terms/carers-gallbladder-cancer-uk/>, <https://onco.cc/terms/biliary-stent/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/metaplasia-dysplasia-carcinoma-sequence/>, <https://onco.cc/terms/intracholecystic-papillary-tubular-neoplasm/>, <https://onco.cc/terms/salmonella-typhi-gallbladder-cancer/>, <https://onco.cc/terms/her2-testing-in-biliary-cancer/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/her2-positive/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/>, <https://onco.cc/terms/biliary-drainage-routes/>, <https://onco.cc/terms/duodenal-stenting-gastric-outlet/>, <https://onco.cc/terms/gallbladder-cancer-symptom-control/>, <https://onco.cc/terms/prophylactic-cholecystectomy/> ;
  onco:trials <https://onco.cc/trials/bilcap/>, <https://onco.cc/trials/topaz-1/>, <https://onco.cc/trials/keynote-966/>, <https://onco.cc/trials/abc-02/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/trials/abc-06/>, <https://onco.cc/trials/mypathway/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/trials/acticca-1/>, <https://onco.cc/trials/ascot-jcog1202/>, <https://onco.cc/trials/swog-s0809/>, <https://onco.cc/trials/opt-in/>, <https://onco.cc/trials/gain-igbc/>, <https://onco.cc/trials/polcagb/>, <https://onco.cc/trials/neogb/>, <https://onco.cc/trials/rugb/>, <https://onco.cc/trials/debate/>, <https://onco.cc/trials/swog-s1815/>, <https://onco.cc/trials/gap-phase2-mdacc/>, <https://onco.cc/trials/nifty/>, <https://onco.cc/trials/nife/>, <https://onco.cc/trials/treetopp/>, <https://onco.cc/trials/eortc-1607-pembro-cisgem/>, <https://onco.cc/trials/sevilla/>, <https://onco.cc/trials/safir-abc10/>, <https://onco.cc/trials/determine-arm04/>, <https://onco.cc/trials/abc-07/>, <https://onco.cc/trials/abc-12/>, <https://onco.cc/trials/ea2197-ivonescimab/>, <https://onco.cc/trials/combomatch-binimetinib-folfox/>, <https://onco.cc/trials/trap-btc/>, <https://onco.cc/trials/tesla-rct/>, <https://onco.cc/trials/herizon-btc-01/>, <https://onco.cc/trials/roar/>, <https://onco.cc/trials/keynote-158/>, <https://onco.cc/trials/nct05482516/>, <https://onco.cc/trials/nct07062263/>, <https://onco.cc/trials/nct07745296/>, <https://onco.cc/trials/nct06037980/>, <https://onco.cc/trials/nct06355427/>, <https://onco.cc/trials/nct06662877/>, <https://onco.cc/trials/nct07437287/>, <https://onco.cc/trials/nct07598318/>, <https://onco.cc/trials/nct02151084/>, <https://onco.cc/trials/nct02632305/>, <https://onco.cc/trials/nct03364530/>, <https://onco.cc/trials/nct03482102/>, <https://onco.cc/trials/nct03801083/>, <https://onco.cc/trials/nct03937830/>, <https://onco.cc/trials/nct04005339/>, <https://onco.cc/trials/nct04042831/>, <https://onco.cc/trials/nct04183712/>, <https://onco.cc/trials/nct04238637/>, <https://onco.cc/trials/nct04634058/>, <https://onco.cc/trials/nct04910386/>, <https://onco.cc/trials/nct04941287/>, <https://onco.cc/trials/nct04969887/>, <https://onco.cc/trials/nct05170438/>, <https://onco.cc/trials/nct05222971/>, <https://onco.cc/trials/nct05422690/>, <https://onco.cc/trials/nct05451043/>, <https://onco.cc/trials/nct05451290/>, <https://onco.cc/trials/nct05640791/>, <https://onco.cc/trials/nct05705492/>, <https://onco.cc/trials/nct05724563/>, <https://onco.cc/trials/nct05733000/>, <https://onco.cc/trials/nct05757336/>, <https://onco.cc/trials/nct05985707/>, <https://onco.cc/trials/nct06001658/>, <https://onco.cc/trials/nct06037655/>, <https://onco.cc/trials/nct06048133/>, <https://onco.cc/trials/nct06135896/>, <https://onco.cc/trials/nct06230471/>, <https://onco.cc/trials/nct06274879/>, <https://onco.cc/trials/nct06280508/>, <https://onco.cc/trials/nct06389500/>, <https://onco.cc/trials/nct06423170/>, <https://onco.cc/trials/nct06438822/>, <https://onco.cc/trials/nct06490107/>, <https://onco.cc/trials/nct06502080/>, <https://onco.cc/trials/nct06530823/>, <https://onco.cc/trials/nct06531291/>, <https://onco.cc/trials/nct06591650/>, <https://onco.cc/trials/nct06620848/>, <https://onco.cc/trials/nct06638931/>, <https://onco.cc/trials/nct06654947/>, <https://onco.cc/trials/nct06708858/>, <https://onco.cc/trials/nct06717464/>, <https://onco.cc/trials/nct06728410/>, <https://onco.cc/trials/nct06789848/>, <https://onco.cc/trials/nct06852287/>, <https://onco.cc/trials/nct06892925/>, <https://onco.cc/trials/nct06901622/>, <https://onco.cc/trials/nct06903273/>, <https://onco.cc/trials/nct06919848/>, <https://onco.cc/trials/nct06963060/>, <https://onco.cc/trials/nct06993025/>, <https://onco.cc/trials/nct07003815/>, <https://onco.cc/trials/nct07025174/>, <https://onco.cc/trials/nct07036380/>, <https://onco.cc/trials/nct07062536/>, <https://onco.cc/trials/nct07099794/>, <https://onco.cc/trials/nct07105852/>, <https://onco.cc/trials/nct07109167/>, <https://onco.cc/trials/nct07129018/>, <https://onco.cc/trials/nct07135544/>, <https://onco.cc/trials/nct07146646/>, <https://onco.cc/trials/nct07151872/>, <https://onco.cc/trials/nct07159204/>, <https://onco.cc/trials/nct07159217/>, <https://onco.cc/trials/nct07160283/>, <https://onco.cc/trials/nct07263360/>, <https://onco.cc/trials/nct07267078/>, <https://onco.cc/trials/nct07282262/>, <https://onco.cc/trials/nct07282912/>, <https://onco.cc/trials/nct07296666/>, <https://onco.cc/trials/nct07310069/>, <https://onco.cc/trials/nct07351591/>, <https://onco.cc/trials/nct07433673/>, <https://onco.cc/trials/nct07471165/>, <https://onco.cc/trials/nct07472933/>, <https://onco.cc/trials/nct07478523/>, <https://onco.cc/trials/nct07506057/>, <https://onco.cc/trials/nct07514533/>, <https://onco.cc/trials/nct07530445/>, <https://onco.cc/trials/nct07561775/>, <https://onco.cc/trials/nct07569679/>, <https://onco.cc/trials/nct07570849/>, <https://onco.cc/trials/nct07599995/>, <https://onco.cc/trials/nct07623642/>, <https://onco.cc/trials/nct07631884/>, <https://onco.cc/trials/nct07635290/>, <https://onco.cc/trials/nct07636824/>, <https://onco.cc/trials/nct07638501/>, <https://onco.cc/trials/nct07649980/>, <https://onco.cc/trials/nct07654530/>, <https://onco.cc/trials/nct07668453/>, <https://onco.cc/trials/nct07670273/>, <https://onco.cc/trials/nct07679399/>, <https://onco.cc/trials/nct07701122/>, <https://onco.cc/trials/nct07704177/>, <https://onco.cc/trials/nct07723534/>, <https://onco.cc/trials/nct07726446/>, <https://onco.cc/trials/nct07729033/>, <https://onco.cc/trials/nct07729917/>, <https://onco.cc/trials/nct07733115/>, <https://onco.cc/trials/nct07767994/>, <https://onco.cc/trials/nct07780838/>, <https://onco.cc/trials/nct07786766/>, <https://onco.cc/trials/nct07793253/>, <https://onco.cc/trials/nct07797816/>, <https://onco.cc/trials/nct07829874/>, <https://onco.cc/trials/nct07831993/>, <https://onco.cc/trials/nct04068194/>, <https://onco.cc/trials/nct04645160/>, <https://onco.cc/trials/nct04781192/>, <https://onco.cc/trials/nct05000294/>, <https://onco.cc/trials/nct05749900/>, <https://onco.cc/trials/nct05849480/>, <https://onco.cc/trials/nct05994001/>, <https://onco.cc/trials/nct06548412/>, <https://onco.cc/trials/nct07269158/>, <https://onco.cc/trials/nct07392541/>, <https://onco.cc/trials/nct07594626/>, <https://onco.cc/trials/nct07632235/>, <https://onco.cc/trials/nct07636798/>, <https://onco.cc/trials/nct06109779/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-early-detection/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/>, <https://onco.cc/key-papers/paper-nakamura-biliary-genomic-spectra-nat-genet-2015/>, <https://onco.cc/key-papers/paper-javle-biliary-ngs-cancer-2016/>, <https://onco.cc/key-papers/paper-wardell-biliary-drivers-germline-j-hepatol-2018/>, <https://onco.cc/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/>, <https://onco.cc/key-papers/paper-weinberg-biliary-profiling-jgo-2019/>, <https://onco.cc/key-papers/paper-pandey-gallbladder-elf3-nat-commun-2020/>, <https://onco.cc/key-papers/paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021/>, <https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/>, <https://onco.cc/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/>, <https://onco.cc/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/>, <https://onco.cc/key-papers/paper-erices-chilean-gallbladder-landscape-front-oncol-2025/>, <https://onco.cc/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/>, <https://onco.cc/key-papers/paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019/>, <https://onco.cc/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/>, <https://onco.cc/key-papers/paper-roa-her2-overexpression-gallbladder-gcr-2014/>, <https://onco.cc/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/>, <https://onco.cc/key-papers/paper-neyaz-pdl1-gallbladder-histopathology-2018/>, <https://onco.cc/key-papers/paper-albrecht-pdl1-western-gallbladder-cancers-2021/>, <https://onco.cc/key-papers/paper-patil-gallbladder-immune-microenvironment-aimm-2021/>, <https://onco.cc/key-papers/paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015/>, <https://onco.cc/key-papers/paper-koshiol-salmonella-typhi-gallbladder-meta-analysis-cancer-med-2016/>, <https://onco.cc/key-papers/paper-roa-gallbladder-preneoplastic-lesions-jso-2006/>, <https://onco.cc/key-papers/paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996/>, <https://onco.cc/key-papers/paper-adsay-icpn-gallbladder-ajsp-2012/>, <https://onco.cc/key-papers/paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021/>, <https://onco.cc/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/>, <https://onco.cc/key-papers/paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019/>, <https://onco.cc/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/>, <https://onco.cc/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/>, <https://onco.cc/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/>, <https://onco.cc/key-papers/paper-harding-lancet-oncol/> ;
  onco:pipeline <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/pairings/gemcis-plus-io-btc/>, <https://onco.cc/trials/safir-abc10/>, <https://onco.cc/trials/sevilla/>, <https://onco.cc/trials/opt-in/>, <https://onco.cc/trials/acticca-1/>, <https://onco.cc/trials/abc-07/>, <https://onco.cc/trials/ea2197-ivonescimab/>, <https://onco.cc/trials/gain-igbc/>, <https://onco.cc/trials/polcagb/>, <https://onco.cc/trials/nct06109779/>, <https://onco.cc/ideas/idea-gbc-report-gallbladder-separately-in-biliary-trials/>, <https://onco.cc/ideas/idea-gbc-national-incidental-cancer-pathway/>, <https://onco.cc/ideas/idea-gbc-t1b-simple-cholecystectomy-prospective-study/>, <https://onco.cc/ideas/idea-gbc-t2a-spare-liver-resection-trial/>, <https://onco.cc/ideas/idea-gbc-reflex-her2-testing-advanced-biliary/>, <https://onco.cc/ideas/idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions/>, <https://onco.cc/ideas/idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated/>, <https://onco.cc/ideas/idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance/>, <https://onco.cc/ideas/idea-gbc-ctdna-residual-disease-guided-adjuvant-trial/>, <https://onco.cc/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/>, <https://onco.cc/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/>, <https://onco.cc/ideas/idea-gbc-burden-to-funding-audit-and-dedicated-call/> ;
  onco:standardOfCare <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/staging-laparoscopy/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/simple-cholecystectomy/>, <https://onco.cc/terms/cystic-duct-margin/>, <https://onco.cc/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/>, <https://onco.cc/terms/radical-cholecystectomy/>, <https://onco.cc/terms/segment-ivb-v-resection/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/cystic-duct-margin/>, <https://onco.cc/terms/port-site-metastasis/>, <https://onco.cc/cancers/incidental-gallbladder-cancer/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/trials/bilcap/>, <https://onco.cc/trials/acticca-1/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/topaz-1/>, <https://onco.cc/trials/keynote-966/>, <https://onco.cc/targets/her2/>, <https://onco.cc/terms/gallbladder-polyp/>, <https://onco.cc/terms/porcelain-gallbladder/>, <https://onco.cc/terms/anomalous-pancreaticobiliary-junction/>, <https://onco.cc/terms/simple-cholecystectomy/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/stent-or-bypass-for-jaundice/>, <https://onco.cc/terms/biliary-stent/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/targets/her2/>, <https://onco.cc/terms/genomic-testing-biliary-uk/>, <https://onco.cc/terms/genomic-profiling/>, <https://onco.cc/terms/trial-or-standard-treatment-biliary/>, <https://onco.cc/terms/clinical-trial/>, <https://onco.cc/terms/informed-consent/>, <https://onco.cc/terms/placebo/>, <https://onco.cc/trials/keynote-966/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/trials/topaz-1/>, <https://onco.cc/trials/abc-07/>, <https://onco.cc/trials/polcagb/>, <https://onco.cc/trials/rugb/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/trials/herizon-btc-01/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/trials/determine-arm04/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/trials/safir-abc10/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/trials/roar/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-158/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/trials/abc-06/>, <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/trials/nifty/>, <https://onco.cc/trials/naliricc/>, <https://onco.cc/trials/sevilla/>, <https://onco.cc/terms/biliary-drainage-routes/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/duodenal-stenting-gastric-outlet/>, <https://onco.cc/terms/gallbladder-cancer-symptom-control/>, <https://onco.cc/technologies/palliative-care/> .